Critical Aortic Stenosis Clinical Trial
— NOTIONOfficial title:
Transcatheter Versus Surgical Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis
Verified date | November 2023 |
Source | Rigshospitalet, Denmark |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A randomized clinical trial of transcatheter aortic valve implantation (TAVI) versus conventional surgical aortic valve replacement (SAVR) in patients older than 70 years of age suffering from severe aortic valve stenosis. Study hypothesis: TAVI will reduce post-interventional morbidity and mortality compared to SAVR.
Status | Active, not recruiting |
Enrollment | 280 |
Est. completion date | April 2033 |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria: - Patients must have severe degenerative aortic valve stenosis (echocardiographic criteria: AV effective orifice area (EOA) of < 1 cm2, mean AV gradient of > 40 mmHg, or AV peak systolic velocity of > 4.0 m/s) - Patients must be symptomatic from the aortic valve stenosis (dyspnoea in NYHA-class II or greater, angina pectoris, or syncope), or asymptomatic but with echocardiographic evidence of left ventricular hypertrophy, decreased left ventricular ejection fraction, or atrial fibrillation) - Patients must be 70 years or older - Patients must be technical and anatomical eligible for both interventions (as specified by Medtronic CoreValve(TM) for the TAVI procedure) after a formal consult by a cardiologist and a cardiovascular surgeon - Patients must be expected to survive more than one year after the intervention - Patients must be able to provide written informed consent as approved by the regional ethical committee after having received adequate information about the study - Patients must be able and agree to return to all post-procedural follow-up visits Exclusion Criteria: - Isolated aortic valve insufficiency - Other significant heart valve disease requiring intervention - Coronary artery co-morbidity requiring revascularisation - Any previous open heart surgery - Myocardial infarction or percutaneous coronary intervention within the last year - Stroke or TIA within the last 30 days - Renal insufficiency requiring hemodialysis - Pulmonary insufficiency (FEV1 or diffusion capacity < 40% of expected) - Active infectious disease requiring antibiotics - Emergency intervention (within 24 hours after the indication for intervention has been made) - Unstable pre-interventional condition requiring inotropic support or mechanical heart assistance - A known hypersensitivity or contraindication to heparin or nitinol - Currently participating in an investigational drug or another device study |
Country | Name | City | State |
---|---|---|---|
Denmark | Copenhagen University Hospital | Copenhagen | |
Denmark | Odense University Hospital | Odense | |
Sweden | Sahlgrenska University Hospital | Gothenburg |
Lead Sponsor | Collaborator |
---|---|
Rigshospitalet, Denmark | Copenhagen Trial Unit, Center for Clinical Intervention Research, Danish Heart Foundation, Odense University Hospital, Sahlgrenska University Hospital, Sweden |
Denmark, Sweden,
Geisler BP, Jorgensen TH, Thyregod HGH, Pietzsch JB, Sondergaard L. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk: results from the NOTION trial. EuroIntervention. 2019 Dec 6;15(11):e959-e9 — View Citation
Gronlykke L, Ihlemann N, Ngo AT, Thyregod HG, Kjaergaard J, Korshin A, Gustafsson F, Hassager C, Nilsson JC, Sondergaard L, Ravn HB. Measures of right ventricular function after transcatheter versus surgical aortic valve replacement. Interact Cardiovasc T — View Citation
Jorgensen TH, Thyregod HG, Tarp JB, Svendsen JH, Sondergaard L. Temporal changes of new-onset atrial fibrillation in patients randomized to surgical or transcatheter aortic valve replacement. Int J Cardiol. 2017 May 1;234:16-21. doi: 10.1016/j.ijcard.2017 — View Citation
Jorgensen TH, Thyregod HGH, Ihlemann N, Nissen H, Petursson P, Kjeldsen BJ, Steinbruchel DA, Olsen PS, Sondergaard L. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve re — View Citation
Ngo A, Hassager C, Thyregod HGH, Sondergaard L, Olsen PS, Steinbruchel D, Hansen PB, Kjaergaard J, Winther-Jensen M, Ihlemann N. Differences in left ventricular remodelling in patients with aortic stenosis treated with transcatheter aortic valve replaceme — View Citation
Sondergaard L, Ihlemann N, Capodanno D, Jorgensen TH, Nissen H, Kjeldsen BJ, Chang Y, Steinbruchel DA, Olsen PS, Petronio AS, Thyregod HGH. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. J Am Coll — View Citation
Sondergaard L, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Ngo AT, Olsen NT, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Olsen PS, Thyregod HG. Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcath — View Citation
Thyregod HG, Sondergaard L, Ihlemann N, Franzen O, Andersen LW, Hansen PB, Olsen PS, Nissen H, Winkel P, Gluud C, Steinbruchel DA. The Nordic aortic valve intervention (NOTION) trial comparing transcatheter versus surgical valve implantation: study protocol for a randomised controlled trial. Trials. 2013 Jan 9;14:11. doi: 10.1186/1745-6215-14-11. — View Citation
Thyregod HG, Steinbruchel DA, Ihlemann N, Ngo TA, Nissen H, Kjeldsen BJ, Chang Y, Hansen PB, Olsen PS, Sondergaard L. No clinical effect of prosthesis-patient mismatch after transcatheter versus surgical aortic valve replacement in intermediate- and low-r — View Citation
Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen LW, Olsen PS, Sondergaard L. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Ao — View Citation
Thyregod HGH, Ihlemann N, Jorgensen TH, Nissen H, Kjeldsen BJ, Petursson P, Chang Y, Franzen OW, Engstrom T, Clemmensen P, Hansen PB, Andersen LW, Steinbruuchel DA, Olsen PS, Sondergaard L. Five-Year Clinical and Echocardiographic Outcomes From the NOTION — View Citation
* Note: There are 11 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Combined rate of death from any cause, myocardial infarction, and stroke | Outcome measures will be defined as suggested by the Valvular Academic Research Consortium (VARC) | 1 year | |
Secondary | Procedural complications | Within first 30 days | ||
Secondary | Admission lengths (ICU and interventional center) | Within first 30 days | ||
Secondary | Combined rate of noncardiac and cardiac death, prosthesis reintervention, cardiac-, cerebral-, renal-, and pulmonary complications | 1 year | ||
Secondary | Functional status (NYHA-classification) and Quality of Life (SF-36) | 1 year | ||
Secondary | Echocardiographic prosthesis and ventricular structural and functional status | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00530894 -
THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial
|
N/A |